Enhancing remyelination is a key therapeutic strategy for demyelinating diseases such as multiple sclerosis. To achieve this goal, a central challenge is being able to quantitatively and longitudinally track functional remyelination, especially with translatable biomarkers that can be performed in both preclinical models and in the clinic. We developed the methodology to stably measure multi-modal sensory evoked potentials from the skull surface over the course of months in individual mice and applied it to a genetic mouse model of oligodendrocyte ablation and demyelination. We found that auditory and somatosensory evoked potential latencies reliably increased over time during the early phase of the model and recovered spontaneously and almost completely during a later phase. Histological examination supported the interpretation that the evoked potential latency changes dynamically reflect changes in CNS myelination. Specifically, we found reduction of myelination in corresponding brain regions at the time that sensory evoked potentials were maximally impacted. Importantly, we also found that myelination levels recovered when evoked potential latencies recovered. Other changes known to associate with demyelination were also observed at the time of delayed evoked potentials, including the emergence of white matter vacuoles and increased markers for activated microglia and macrophages; these changes also fully reversed by the time that evoked potentials recovered. Our results support the hypothesis that skull-surface recorded evoked potential latencies can dynamically track CNS myelination changes. The methods developed here allow for longitudinally tracking functional myelination changes in vivo in preclinical rodent models with a quantitative biomarker that can also be applied clinically and will facilitate translational development of CNS remyelinating therapies.
Introduction
There is significant unmet medical need for therapies that address the progressive phase of multiple sclerosis (MS), which is characterized by low grade inflammation, chronic demyelination and axonal degeneration, leading to progressive accumulation of disability (Lassmann, 1999; McDonald and Ron, 1999) . Enhancing remyelination is one proposed therapeutic strategy for progressive MS because myelin plays a protective, trophic role for axons in addition to enabling saltatory conduction (Hagemeier et al., 2012; Schirmer et al., 2018; Verden and Macklin, 2016) . Spontaneous remyelination does occur for some MS lesions, and prognosis is better for patients that remyelinate more efficiently (Bodini et al., 2016; Patrikios et al., 2006) . Encouragingly, numerous compounds that enhance the remyelination process have been demonstrated in preclinical models in vitro and in vivo Cole et al., 2017; Deshmukh et al., 2013; MedinaRodríguez et al., 2017; Mei et al., 2014; Mi et al., 2007) . However, translating these preclinical results into therapies will benefit from the availability of objective, quantitative and feasible biomarkers of functional remyelination in animal models and patients. Validated biomarkers of in vivo remyelination and their application to preclinical models of demyelination and therapeutic remyelination are currently lacking.
Evoked potentials represent a promising candidate as a translatable biomarker of remyelination . Increased latencies of evoked potentials are thought to reflect demyelination, based on the demonstration in ex vivo preparations that nerve conduction velocity is reduced across the demyelinated portion of an axon (McDonald and Sears, 1970) . In the clinical setting, delayed evoked potentials in response to a sensory stimulus are used to assist in diagnosing patients with focal demyelinating lesions such as in optic neuritis and MS (Halliday et al., 1972) . Importantly, clinical trials utilizing evoked potentials in patients with acute (Cadavid et al., 2017) or chronic (Green et al., 2017) optic neuritis were recently published supporting the role of evoked potentials as biomarkers of therapeutic CNS remyelination. However, given the complex etiology of optic neuritis, which includes inflammation and axonal degeneration in addition to demyelination, attributing evoked potential changes to remyelination per se is difficult in human studies. Measuring evoked potentials in preclinical models of demyelination and therapeutic remyelination would allow for directly relating changes in the biomarker to brain tissue changes, thereby increasing understanding of the biomarker. Toxin-mediated models of demyelination, such as the lysolecithin (LPC) or cuprizone models, are potential preclinical models for this objective (Ransohoff, 2012; Woodruff and Franklin, 1999) . Electrophysiological recordings applied to these models have related conduction changes to remyelination, but have used ex vivo preparations or deep-brain electrode recordings that are not applicable in human studies (Bando et al., 2008; Cerina et al., 2018; Narayanan et al., 2018) . One study examined visual evoked potentials in the lysolecithin model, but only during the demyelination phase (You et al., 2011) . Although evoked potentials are impacted in some inflammatory-mediated demyelination models such as EAE, the stochastic nature of the lesions and concomitant inflammation and axonal degeneration in such models makes relating evoked potential changes to demyelination and remyelination challenging, similarly to the situation faced with clinical studies in MS patients (Balatoni et al., 2007; Ransohoff, 2012) .
An alternative, more recent class of preclinical models of demyelination are based on the genetic ablation of oligodendrocytes (Caprariello et al., 2012; Ghosh et al., 2011; Locatelli et al., 2012; Pohl et al., 2011; Traka et al., 2010; Wan and Corfas, 2017) . In one such model, herein referred to as the "DTA" model, a widespread CNS demyelination process without axonal loss has been described, followed by spontaneous remyelination (Traka et al., 2016 (Traka et al., , 2010 Wan and Corfas, 2017) . A recent study reported that Schwann cells can also be regionally impacted in this model depending on the animal age (Wan and Corfas, 2017) . Here, we used the DTA model to demonstrate reliable longitudinal measures of multi-modal sensory evoked potentials and asked whether evoked-potential changes could reliably track histological CNS demyelination and remyelination.
Materials and methods

Mice, treatment groups, and clinical evaluation
Experimental protocols were approved by the Biogen IACUC and followed AAALAC guidelines. These studies used male Rosa26-DTA; PLP-CreER T mice (Traka et al., 2010) . DTA transgene expression was induced in mice that were 8-11 weeks old by daily intraperitoneal administration of 0.5 mg 4-hydroxytamoxifen (Sigma H6278; 5 mg/mL solution in 4% DMSO, 6% ethanol, 90% sesame oil, v/v) for 5 consecutive days. At this tamoxifen dose, approximately 15% of mice reached a clinical stage from which they were not expected to recover and were euthanized (usually between 3 and 6 weeks after tamoxifen administration), and data from these mice are not included in this study. Rosa26-DTA; PLP-Cre mice induced with tamoxifen in this way are referred to as "DTA" mice throughout the manuscript; in contrast, "control" mice had the same genotype but were injected with vehicle solution. In one additional experiment, which tested for direct side effects induced by tamoxifen, we injected Rosa26-DTA mice (without the PLP-Cre transgene) with the tamoxifen induction protocol detailed above. Tamoxifen injections in mice without the PLP-Cre transgene failed to reproduce any of the evoked potential, CMAP, or behavioral phenotypes described in this study ( Supplementary Fig. 1 ). Thus, the effects described in the study are the downstream result of tamoxifendependent action of Cre recombinase, and not a side effect of tamoxifen. To qualitatively assess the disease course, a clinical score scale was devised and performed once per week for each mouse by raters blinded to genotype and treatment condition. In this ordinal scale, higher numbers correspond to the presence of more severe phenotypes, although increasing scores are not linearly proportional to severity (1 = normal motor function; 2 = minor gait alteration; 3 = minor gait alteration and hind limb clasping; 4 = gait alteration, hindlimb clasping, and tremor with movement; 5 = gait alteration, hindlimb clasping, and tremor during both rest and movement).
Surgeries
Surgeries were performed under isoflurane anesthesia to effect, and with lidocaine applied to incision points. Body temperature was maintained at 37°C. Stainless steel screws were implanted bilaterally on the dorsal surface of the skull near either the auditory cortex, visual cortex, or the somatosensory cortex hind limb representation area. Additionally, 2 screws were implanted over the cerebellum to serve as reference and ground electrodes, respectively. For visual evoked potentials, we additionally affixed a 3 mm red LED light on the edge of the skull directly over the left and right eyes, allowing light stimulation in freely-moving mice. Wires attached to the electrodes and LEDs were run up to a connector (Plastics One) which provided electrical access to the electrodes and LEDs during recordings. The electrodes and connector were embedded in Metabond (Parkell, Edgewood, NY) cement followed by Integrity epoxy. Animals recovered from surgery for at least 5 days before evoked potentials were recorded.
2.3. In-vivo auditory, somatosensory, and visual evoked potential (AEP, SSEP, VEP) and compound muscle action potential (CMAP) recordings AEPs and VEPs were recorded from non-anesthetized, freely moving mice in their home cage. The cage was placed with its lid removed in a dark, sound-attenuating chamber. One end of a flexible wire tether was attached to the cranial implant connector on the mouse, with the other end connected to a commutator above the mouse's cage and subsequently to the data acquisition system. AEPs were obtained by measuring the average response evoked in auditory cortex by 200 white noise bursts, each 15 ms long and separated by 10 s, produced by a freefield speaker placed at the top of the chamber. For VEPs, animals were dark adapted for 20 min. The VEP was obtained separately in response to stimulation of the left and right eye by the implanted LED light source. In each case, the averaged response evoked by 400 LED light flashes, each 5 ms long and separated by 3 s, was measured from the contralateral visual cortex. SSEP and CMAP recordings were performed under isoflurane anesthesia, by measuring the average responses evoked by 50 electrical stimuli (0.1 ms long square-wave pulse of 0.4 mA), each separated by 2 s, applied near the sciatic nerve. Responses were measured simultaneously from the somatosensory cortex hind limb area (for the SSEP) or from the tibialis anterior muscle of the hind limb (for the CMAP). For all evoked potentials (AEP, VEP and SSEP), signals were sampled at 4 kHz and bandpass filtered between 1 and 500 Hz. For CMAP, the EMG signal was sampled at 24 kHz and bandpass filtered between 100 and 3000 Hz. In all cases, two separate AEP, VEP, SSEP, or CMAP recording sessions separated by at least one day were performed before tamoxifen or vehicle administration and served as "baseline" recordings; subsequent recordings were recorded at regular intervals (weekly or bi-weekly) beginning one week after tamoxifen or vehicle administration. For SSEPs we measured the amplitude and latency of the first positive (shown upward) deflection in the response waveform from each recording session. For VEPs, we measured the amplitude and latency of the first negative deflection in the response waveform. For AEPs, the response could have multiple peaks, but we quantified the amplitude and latency of the largest positive peak. In all cases, evoked potential peaks were detected automatically with an algorithm, but waveforms from all individual recordings were also visually inspected to ensure that the same response component from each individual mouse was being tracked over time. For the CMAP, we quantified the peak-to-peak amplitude of the biphasic response waveform, and the latency of the 1st peak. The evoked potential amplitudes and latencies of the two pre-tamoxifen recordings were obtained and averaged to obtain baseline amplitude and latency measures (of AEP, VEP, SSEP or CMAP) for each mouse. Subsequent amplitude and latency measurements were then normalized to each animal's baseline value. Normalization allowed easier comparison of response behavior across measures, but the same results and conclusions held without this step.
Histochemistry
From a cohort of mice injected on the same day with either vehicle (control) or tamoxifen (DTA) solution, every other mouse from each group (after ordering by identification number) was randomly selected to be sacrificed after 8 weeks, and the remaining sacrificed after 14 weeks. Mice were perfused in heparin/saline followed by 10% neutral buffered formalin. Immediately following perfusion, the brain was removed with cervical spinal cord attached and post-fixed in ethanol for 96 h. Brains were dehydrated through graded alcohols and xylene, infiltrated with paraffin wax and subsequently embedded in a paraffin block. Tissue blocks were stored at room temperature. Subsequent steps were performed for all 8-week and 14-week control and DTA mice at the same time. From each mouse, five consecutive 5 μm whole-brain coronal sections were collected every 500 μm, beginning several millimeters rostral to Bregma and continuing caudally several millimeters into the cervical spinal cord. Alternate sections at each level were processed for different stains, as described below. Processing was performed in batches such that each batch contained a subject from each experimental group (control and DTA mice, each at 8-weeks and 14-weeks) to ensure that group differences could not be accounted for by differences across batches. Immunohistochemical staining was performed using a Lab Vision Autostainer 360 (LabVision, Fremont, CA). Slides were rehydrated through xylene and graded alcohols. For Iba1 immunohistochemistry, after rehydration slides underwent a heat-induced antigen retrieval in boiling 10 mM citrate buffer pH 6.0 (LabVision) at elevated pressure. Samples were treated to quench endogenous peroxidase activity with 0.3% H 2 O 2 followed by protein blocking with LVBlock (LabVision). Sections were incubated with the appropriate primary antibodies: For MBP, mouse anti-myelin basic protein (1:1000; BioLegend, catalog #808401) and for Iba-1 rabbit polyclonal anti-Iba1 (Wako, 1:1000Cat # 019-19741). Primary antibody binding was amplified using Complement reagent, HRPConjugate, and visualized using AEC Single Solution (Spring Bioscience). All immunohistochemistry sections were counterstained with Acid Blue 129 (Sigma-Aldrich, St. Louis, MO) and mounted with aqueous mounting medium (Zehntner et al., 2008) . For Luxol Fast Blue/ H&E, after rehydration slides were stained in 60°C pre-warmed Luxol Fast Blue 38 (Santa Cruz, CAT sc-215892) for 60 min. Staining was then differentiated in 0.05% lithium carbonate (Sigma-Aldrich, Cat # 62470-100G-F) for 30 s. After washing, slides were counterstained using the Leica hematoxylin and eosin staining system (consisting of Hematoxylin 560, Blue Buffer 8, Define and Alcoholic Eosin Y 515 h). Slides were dehydrated and mounted in xylene based mounting medium. Quantitative analyses were restricted to 2 brain regions of interest, including cervical spinal cord (white matter regions only) and brainstem (entire section). For quantification of MBP staining, the mean staining intensity across each region of interest was measured in each mouse. Iba1 staining was quantified as the percentage of Iba1-positive pixels, using a constant empirically-defined threshold. Vacuoles were quantified as the percentage of Luxol Fast Blue/H&E negative pixels, using a constant empirically-defined threshold. Image analyses were performed using ImageJ.
Results
Transgenic mouse model of induced oligodendrocyte loss and demyelination
For these studies, we employed the Rosa26-DTA/PLP-CreER T ("DTA") inducible transgenic mouse model, where induction by tamoxifen results in rapid apoptosis of oligodendrocytes followed by demyelination and later spontaneous remyelination (Traka et al., 2010; Traka et al., 2016) . For induction of the model, we used a tamoxifen dose (0.5 mg/day for 5 days) that was two-fold lower than in previously-published studies, in order to limit the severity of the clinical phenotype. Consistent with previous reports, DTA mice exhibited a motor phenotype whose signs as measured by a composite clinical score peaked around 4-8 weeks after tamoxifen induction, with subsequent spontaneous recovery occurring over the following weeks (Fig. 1 Fig. 1d ).
Evoked potentials track the expected time-course of CNS demyelination and remyelination in DTA mice
With the goal of validating a method to quantitatively track functional myelination levels in sensory pathways impacted in demyelinating diseases, we developed chronic in vivo evoked potential recording methods and applied them to the DTA mouse model. Evoked potentials could be stably and reliably recorded from the mice over the course of months. AEPs were recorded from non-anesthetized, freely moving mice in response to a white noise sound. The AEP waveform had multiple components, but the most prominent peak was a positivity with a latency of approximately 20 ms (Fig. 2a) . In control mice, the AEP waveform morphology was stable across time, with the mean latency and amplitude of the positive peak remaining stable over a 14-week period following vehicle injection (Fig. 2b-d) . In contrast, AEPs from DTA mice displayed a progressive increase in their latencies across time that peaked around 8 weeks following tamoxifen injection ( Fig. 2b  and d) . After 8 weeks, a gradual and substantial recovery occurred, and by week 14 latencies were not different between DTA and control mice ( Fig. 2b and d) . This same pattern of AEP latency changes was visible in all 12 tamoxifen-injected mice in the study (data not shown), underscoring the consistency of the DTA model and AEP recording methodology. In contrast with AEP latency, changes in AEP amplitude were more variable between mice, although lower amplitudes were evident at intermediate timepoints and reached significance at the 7-week timepoint (Fig. 2c) . Importantly, AEP amplitudes were never reduced to zero, indicating that while conduction time increased in the auditory pathway, a complete conduction block never occurred. Overall, these results demonstrate that AEP latencies show reliable, dynamic changes across time in the DTA model of oligodendrocytes loss. In later results, we describe the relationship between these functional changes and myelination-related changes in the brain.
To determine whether changes in CNS conduction across sensory pathways could be measured from a second sensory modality, we recorded SSEPs in an additional experiment. The SSEP in mouse, which was measured under isoflurane anesthesia, was composed of a monophasic waveform with a positive peak whose latency was approximately 15 ms (Fig. 3a) . In DTA mice, SSEPs showed a similar pattern of changes across time as were observed for AEPs. Namely, while SSEP waveforms from control mice exhibited stable latencies across time, SSEPs from DTA mice displayed a progressive increase in their latencies that peaked around 8 weeks following tamoxifen injection ( Fig. 3b and d) . Following week 8, SSEP latencies recovered substantially, and SSEP latencies were no longer different between DTA and control mice by week 14 (Fig. 3b and d) . The amplitudes of SSEPs were also measured. SSEP amplitudes were more variable than latencies, but a trend towards reduced SSEP amplitude was evident in DTA mice compared to control mice and reached significance at several intermediate timepoints (Fig. 3c) . Thus, similarly to AEPs, SSEP amplitudes were reduced in DTA mice but complete conduction block was not observed at any timepoint. On a practical note, the AEP and SSEP results taken together indicate that longitudinal changes to neural conduction can be tracked in the DTA model either in the awake animal (AEPs) or under anesthesia (SSEPs).
Because the visual system is an additional sensory modality that can be impacted in demyelinating diseases, we also established methodology to chronically measure VEPs in DTA mice. In control mice, stable VEP latencies could be measured across the 14-week time course of the experiments, although a gradual reduction in amplitudes was evident ( Supplementary Fig. 2 ). In clear contrast to AEPs and SSEPs, however, we found that VEPs were unchanged in DTA mice relative to control mice at any timepoint. This observation was made in a cohort of mice from which AEP changes and a clinical phenotype were observed. Thus, neural conduction was not impacted in a measurable way across all sensory pathways examined in the DTA model (see Discussion). Given the clear impact of the model on AEPs and SSEPs, subsequent efforts were focused on describing cellular and molecular changes in brain regions associated with these affected sensory pathways.
Reduction and subsequent recovery of myelination-related molecular markers in DTA mice
The results above indicate that AEP and SSEP latencies progressively increase, and subsequently recover, in the DTA model. To determine the origin of the observed evoked potential latency changes, histological analyses were performed in DTA and control mice in corresponding CNS regions at key selected timepoints following model induction. Specifically, tissue was analyzed in control and DTA mice after 8 weeks when evoked potential latencies are maximally impacted, or after 14 weeks when latencies have recovered. Importantly, all mice in the histological analyses were induced together, and were randomly grouped for processing at one of the two timepoints. We confirmed that the clinical progression was similar by the week 8 timepoint in both groups, and that clinical recovery occurred in the week 14 group (Supplementary Fig. 3 ).
To measure myelination-related changes, we first analyzed myelinbasic protein staining levels in white matter regions from cervical spinal cord sections, given that somatosensory fibers course through this CNS region. At the 8-week timepoint following model induction, the levels were significantly reduced in DTA mice relative to control mice ( Fig. 4a  and b) . Thus, myelin-basic protein levels are reduced in the spinal cord of DTA mice when SSEP latencies are prolonged (see Fig. 3 ). Further, myelin basic protein levels recovered in the spinal cord of DTA mice between the 8 and 14-week timepoints, being significantly higher at the latter timepoint ( Fig. 4a and b) . This indicates that myelin basic protein levels recover during the same time period as SSEP latencies (see Fig. 3 ) and supports the hypothesis that evoked potential latency recovery is a biomarker of remyelination. Myelin basic protein levels were also analyzed in the brainstem, given that both auditory and somatosensory fibers course through this region. We found a similar pattern of changes in myelin basic protein levels in brainstem as in spinal cord. Specifically, MBP levels were significantly reduced in week 8 DTA mice relative to control mice; further, a trend towards recovered MBP levels was observed in 14-week DTA mice relative to 8-week DTA mice, although it did not reach significance ( Fig. 4c and d) .
A phenomenon which commonly accompanies demyelination is vacuolation, which has been suggested to arise in part due to the splitting of myelin lamellae as demyelination proceeds in this model (Traka et al., 2010) . Thus, as a second independent way to quantify myelination-related processes, we measured vacuoles in spinal cord white matter regions following Luxol Fast Blue/H&E histochemistry. We observed a significant increase in the presence of vacuoles in DTA mice relative to control mice 8 weeks following model induction ( Fig. 5a and b) . Strikingly, however, vacuole presence was strongly reduced in week 14 DTA mice relative to week 8 DTA mice, and vacuole levels were no longer different between DTA and control mice by week 14 (Fig. 5a and b) . Thus, the vacuolation results provide additional evidence of a demyelination-related phenotype in week 8 DTA mice, which subsequently recovers by the 14-week timepoint.
An additional process associated with demyelination is the activation of resident CNS microglia and peripheral macrophages (Brion, 1976; Luo et al., 2017; Traka et al., 2010) . To look at these cell types, we therefore performed immunohistochemistry with the microglia and macrophage marker Iba1. Visual inspection of Iba1-stained spinal cord sections from week 8 DTA mice indicated elevated Iba1 staining, particularly in white matter tracts involved in SSEP conduction such as the posterior columns (Fig. 6a) . Iba1 levels were significantly increased in spinal cord of week 8 DTA mice relative to control mice (Fig. 6b) . However, by week 14 the Iba1 levels in DTA mice were no longer elevated and were not distinguishable from control mice (Fig. 6b) . These results indicate that in DTA mice, microglia and macrophages are elevated when demyelination is observed and during the peak time of the clinical and evoked potential phenotypes, but subsequently return to normal levels.
Neuronal conduction in the PNS of DTA mice
To explore whether the latency changes measured in AEPs and SSEPs reflect central nervous system (CNS) changes, or whether peripheral effects drive these changes, we also tracked peripheral nervous system (PNS) conduction, as indexed by the compound muscle action potential (CMAP) in DTA mice. The results indicated a pronounced impact on CMAP in DTA mice, but with an accelerated time course that was clearly distinct from the time course of evoked potential (AEP and SSEP) changes. Namely, the CMAP was maximally impacted 4 weeks following model induction, but progressively recovered thereafter and was already restored to normal by 7 weeks (Supplementary Fig. 4 ). This indicates that peripheral conduction was recovering when AEP and SSEP changes were worsening (i.e. weeks 4-7; see Figs. 2 and 3) and that peripheral conduction had been almost completely restored by the time AEPs and SSEPs were maximally impacted (week 8). This clear temporal dissociation indicates that peripheral nervous system changes, at least as indexed by the CMAP, do not explain the latency changes observed in AEPs and SSEPs.
Discussion
Enhancing remyelination is a key therapeutic goal in MS research. However, there is currently a lack of validated in vivo translatable biomarkers of functional remyelination, which would allow this process to be longitudinally measured and compared in both animal models and human subjects. In this study, we characterize the DTA mouse model which is based on the inducible ablation of oligodendrocytes. By developing methods to stably measure in vivo evoked potentials from individual mice over the course of months, and characterizing accompanying histological changes, we establish a clear bidirectional relationship between evoked potentials and in vivo myelination. We suggest that employing the measurements used here in the DTA or other models could facilitate the monitoring of in vivo remyelination dynamics and allow for the evaluation of potential remyelination-enhancing therapeutics with a biomarker which is translatable to the clinic.
Evoked potentials as biomarkers of demyelination and remyelination
In this study, we describe week-by-week changes in evoked potential latencies in DTA mice, over the course of 3.5 months. The pattern of changes observed is consistent with the hypothesis that in vivo evoked potential latencies measurable from the skull surface reflect changes in CNS myelination. Namely, increased evoked potential latencies were observed from auditory and somatosensory pathways at a time when reductions in myelin basic protein levels were present in corresponding CNS regions. Further, evoked potential latencies subsequently recovered when myelin levels recovered in the tissue. This bidirectional relationship, observed in a non-T cell mediated disease model, provides strong evidence that evoked potential latencies represent a biomarker of demyelination and remyelination. The bidirectional relationship between skull electrode-recorded sensory evoked potential latencies and myelination described here is consistent with that reported in earlier studies that have used ex vivo preparations or deep-brain electrode recordings (Bando et al., 2008; Cerina et al., 2018; Narayanan et al., 2018) . Our results are also consistent with a report that evoked potential latencies increase during the demyelination phase of the mouse lysolecithin (LPC) model (You et al., 2011) .
In addition to latencies of evoked potentials, their amplitudes can also be informative as a biomarker. For example, in an exploratory analysis from the optic neuritis clinical trial of Opicinumab, treatment effects were shown for multifocal VEP amplitudes (Klistorner et al., 2018) . Our results indicate that evoked potential amplitudes are reduced at the time of demyelination in the DTA model and recover at the time of remyelination. Although we did not assess axonal injury histologically in this study, the recovery of the amplitudes suggests that axonal degeneration is not primarily responsible for their earlier reduction, given that CNS axonal degeneration is a naturally irreversible process. Further, axonal degeneration is not a prominent feature of the phase of the DTA mouse model studied here (Traka et al., 2016 (Traka et al., , 2010 . Notably, evoked potentials were not blocked entirely at any point during the 14-week time course of the current study, which allowed quantifying conduction properties throughout the disease process. In a previous study using the DTA model, which employed a two-fold higher dose of tamoxifen, evoked potentials were fully blocked 3 weeks after model induction (Traka et al., 2010) . The reduction of evoked potential amplitudes observed here, which reflect responses in a population of multi-synaptic pathways, could be explained by conduction block owing to demyelination in a subset of fibers, or different degrees of demyelination across fiber types resulting in temporal dispersion and lower amplitude population responses. In either case, subsequent recovery of amplitudes could be explained by remyelination.
It is interesting to note that while myelin basic protein levels recovered completely by week 14 in the model, small differences remained in conduction properties as well as in the clinical score. The lack of full recovery of neural conduction is consistent with longitudinal observations of visual evoked potentials in optic neuritis subjects (Jones and Brusa, 2003) . One contributing factor to incomplete functional recovery in structurally remyelinated systems may relate to the observation of thinner myelin sheaths and shorter internode lengths in remyelinated fibers compared to normal-appearing white matter (Duncan et al., 2017; Ludwin and Maitland, 1984) . Although not studied here, thinner myelination sheaths were previously reported in the DTA model following remyelination (Traka et al., 2010) .
While the DTA model employed here can impact Schwann cells in addition to oligodendrocytes (Wan and Corfas, 2017) , several lines of evidence suggest that the evoked potential changes we observe primarily reflect altered myelination in the CNS rather than the PNS. First, while peripheral nerve transmission was altered, as reflected by CMAP recordings, the time course of CMAP changes were separable from those of centrally-measured SSEPs. Specifically, CMAP was impacted earlier than SSEPs, and fully recovered by the time that SSEPs were maximally impacted. This suggests that PNS conduction changes do not make a significant contribution to prolongation of SSEPs and make no measurable contribution to their recovery. Second, a recent study demonstrated Schwann cell demyelination and remyelination in the auditory pathway, which similar to our CMAP observations occurred early relative to the CNS conduction changes documented here (Wan and Corfas, 2017) . Although a residual impact of 0.2 ms on the latency of auditory brainstem responses was shown, this is an order of magnitude smaller than the AEP latency changes observed here, which were on the order of 5 ms. Third, as mentioned previously, we document clear bidirectional histological changes in CNS structures corresponding to the sensory systems measured functionally. Thus, taken together the results suggest that the evoked potential changes observed here are a biomarker of central rather than peripheral nervous system changes. Nevertheless, future studies would benefit from the employment of animal models that affect myelination in CNS but not PNS.
Although the data described here are consistent with the interpretation that the evoked potential changes reflect CNS myelination, we note that the results are correlational and that other processes could also contribute to changes in neural conduction. Peripherally-mediated inflammation, which accompanies other in vivo models of demyelination and may importantly impact on conduction, is not thought to make an important contribution to the phase of the DTA model studied here (Traka et al., 2016 (Traka et al., , 2010 . On the other hand, the redistribution of ion channels has been described in demyelinated and newly remyelinated CNS axons and likely makes important contributions to changes in axonal conduction (Coman et al., 2006) . Further, we describe here other bidirectional changes occurring in tissue such as vacuolation as well as markers of microglia and peripheral macrophages, which are known to accompany demyelination and remyelination. Further insight into the contribution of these various processes to conduction changes could be revealed by their measurement at additional key timepoints relative to the highly-consistent dynamics of evoked potential changes.
In contrast to the phenotype observed for AEPs and SSEPs in DTA mice, we found no changes in VEPs. Although a previous study reported demyelination in the optic nerve of DTA mice, that study employed a 2-fold higher dose of tamoxifen than used here. Additionally, the pathology in DTA mice has clear regional variability (data not shown), with especially pronounced effects present in regions such as spinal cord and brainstem where somatosensory and auditory, but not visual, fibers course through. We suggest that the level of pathology in the visual pathway under the experimental conditions employed here may not have reached the threshold to affect VEPs.
Employing evoked potentials as translatable biomarkers to evaluate candidate therapeutics
Recent preclinical studies have made progress in identifying drug targets and molecules that influence remyelination Cole et al., 2017; Deshmukh et al., 2013; Medina-Rodríguez et al., 2017; Mei et al., 2014; Mi et al., 2007) . In these preclinical studies, remyelination is typically assessed at single timepoints in post-mortem samples, either by measuring myelin-related mRNA or protein levels or by directly visualizing myelin structure. A near-infrared imaging approach developed for rodent studies allows myelination levels to be longitudinally tracked in vivo (Wang et al., 2011) . These direct measures of myelination can be complemented by behavioral or performance observations in animals, which inform on the possible functional impact of remyelination and repair. While each of these measures can provide critical information relating to remyelination or its functional consequences in preclinical models, none are directly applicable in human studies.
Measuring remyelination in preclinical studies with biomarkers that can also be employed in human subjects would facilitate the process of translating preclinical discoveries into remyelination therapies. Both imaging-and electrophysiology-based methods show promise as translatable biomarkers of myelination (Giacomini and Arnold, 2008; Harlow et al., 2015; Silbermann et al., 2018) . MRI-based approaches such as magnetization transfer ratio (MTR) imaging, diffusion tensor imaging (DTI), and myelin water fraction (MWF) imaging are sensitive to multiple tissue properties including inflammation, edema, axonal density and myelination. Validation studies in preclinical models or using MS tissue have been used to define the relationship between various imaging endpoints and remyelination (Deloire-Grassin et al., 2000; Schmierer et al., 2004) . Such imaging methods have been used to track remyelination in MS patients and to evaluate candidate therapeutics (Brown et al., 2016 (Brown et al., , 2013 Schwartzbach et al., 2017) .
Imaging-based approaches, which reflect the structural properties of tissue, can be complemented by physiological measures, which are sensitive to the functional impact of remyelination. Recent clinical studies of MS and optic neuritis have employed electrophysiology, with several reporting drug-induced enhancement in the recovery of sensory evoked potentials (Cadavid et al., 2017; Green et al., 2017; Klistorner et al., 2018; Raftopoulos et al., 2016) . Combining data from these studies with clinical outcomes will be important for understanding to what degree physiological changes are associated with clinically meaningful improvements (Cadavid et al., 2019) . Additionally, there would be utility in back-translating the clinical findings by testing similar compounds in preclinical experiments with evoked potentials. Preclinical studies would allow for directly relating evoked potential changes to remyelination or other cellular and molecular changes to the tissue. Furthermore, the degree of evoked potential changes resulting from clinically-characterized compounds could serve as a benchmark in evaluating novel drug candidates. In this study, we demonstrate that sensory evoked potentials in the DTA model can be used to longitudinally measure functional myelination in CNS pathways. We suggest that employing evoked potentials in preclinical models is useful for quantitatively tracking remyelination and will aid in translating knowledge between preclinical and clinical studies.
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